

**FOURTH  
EDITION**

# **Viral Hepatitis**

**Edited by**

**Howard C. Thomas**

**Anna S.F. Lok**

**Stephen A. Locarnini**

**Arie J. Zuckerman**

**WILEY** Blackwell





# **Viral Hepatitis**



# Viral Hepatitis

## **EDITED BY**

### HOWARD C. THOMAS

BSc, PhD, FRCP, FRCPath, FMedSci  
*Emeritus Professor of Hepatology*  
*Department of Medicine*  
*Imperial College London*  
*London, UK*

### ANNA S.F. LOK

MD  
*Alice Lohrman Andrews Research Professor in Hepatology*  
*Director of Clinical Hepatology*  
*Professor of Internal Medicine*  
*Associate Chair for Clinical Research, Department of Internal Medicine*  
*University of Michigan Health System*  
*Ann Arbor, MI, USA*

### STEPHEN A. LOCARNINI

MBBS, BSc(Hons), PhD, FRCPath  
*Head, Research & Molecular Development*  
*Victorian Infectious Diseases Reference Laboratory*  
*Melbourne, VIC, Australia*

### ARIE J. ZUCKERMAN

MD, DSc, FRCP, FRCPath, FMedSci  
*Emeritus Professor of Medical Microbiology*  
*Formerly Principal and Dean*  
*Royal Free Hospital School of Medicine, and later*  
*Royal Free and University College Medical School*  
*University College London*  
*London, UK*

## **FOURTH EDITION**

**WILEY** Blackwell

This edition first published 2014 © 2005, 2014 by John Wiley & Sons, Ltd.

*Registered office:* John Wiley & Sons, Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK

*Editorial offices:* 9600 Garsington Road, Oxford, OX4 2DQ, UK  
The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK  
111 River Street, Hoboken, NJ 07030-5774, USA

For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at [www.wiley.com/wiley-blackwell](http://www.wiley.com/wiley-blackwell)

The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988.

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.

Designations used by companies to distinguish their products are often claimed as trademarks. All brand names and product names used in this book are trade names, service marks, trademarks or registered trademarks of their respective owners. The publisher is not associated with any product or vendor mentioned in this book. This publication is designed to provide accurate and authoritative information in regard to the subject matter covered. It is sold on the understanding that the publisher is not engaged in rendering professional services. If professional advice or other expert assistance is required, the services of a competent professional should be sought.

The contents of this work are intended to further general scientific research, understanding, and discussion only and are not intended and should not be relied upon as recommending or promoting a specific method, diagnosis, or treatment by physicians for any particular patient. The publisher and the author make no representations or warranties with respect to the accuracy or completeness of the contents of this work and specifically disclaim all warranties, including without limitation any implied warranties of fitness for a particular purpose. In view of ongoing research, equipment modifications, changes in governmental regulations, and the constant flow of information relating to the use of medicines, equipment, and devices, the reader is urged to review and evaluate the information provided in the package insert or instructions for each medicine, equipment, or device for, among other things, any changes in the instructions or indication of usage and for added warnings and precautions. Readers should consult with a specialist where appropriate. The fact that an organization or Website is referred to in this work as a citation and/or a potential source of further information does not mean that the author or the publisher endorses the information the organization or Website may provide or recommendations it may make. Further, readers should be aware that Internet Websites listed in this work may have changed or disappeared between when this work was written and when it is read. No warranty may be created or extended by any promotional statements for this work. Neither the publisher nor the author shall be liable for any damages arising herefrom.

*Library of Congress Cataloging-in-Publication Data*

Viral hepatitis / edited by Howard C. Thomas . . . [et al.]. – 4th ed.

p. ; cm.

Includes bibliographical references and index.

ISBN 978-0-470-67295-2 (alk. paper) – ISBN 978-1-118-63727-2 (ebook online product)  
– ISBN 978-1-118-63730-2 (ePDF) – ISBN 978-1-118-63731-9 (eMobi) – ISBN 978-1-118-63733-3 (ePub)

I. Thomas, H. C. (Howard C.)

[DNLM: 1. Hepatitis, Viral, Human. 2. Hepatitis Viruses. WC 536]

616.3'623–dc23

2013001678

A catalogue record for this book is available from the British Library.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic books.

Cover image: High detailed hepatitis virus view isolated with clipping path (Image ID: 42546331). © CLIPAREA | Custom media / Shutterstock

Cover design by Garth Stewart

Set in 9.5/12 pt Palatino by Toppan Best-set Premedia Limited

# Contents

List of Contributors, vii

Preface, xii

## Section I: Introduction to Liver Biology

- 1 Liver regeneration and fibrosis, 3  
*Stuart J. Forbes and Malcolm R. Alison*
- 2 Hepatic immunology, 13  
*Gyongyi Szabo and Johanna Bruneau*

## Section II: Hepatitis A Virus

- 3 Structure, molecular virology, natural history, and experimental models, 29  
*Gerardo G. Kaplan, Krishnamurthy Konduru, Mohanraj Manangeeswaran, Jerome Jacques, Nadia Amharref, and Siham Nakamura*
- 4 Epidemiology and prevention, 43  
*Benjamin Cowie and Stephen A. Locarnini*

## Section III: Hepatitis B Virus and Other Hepadnaviridae

- 5 Structure and molecular virology, 65  
*Souphalone Luangsay and Fabien Zoulim*
- 6 Epidemiology and prevention, 81  
*Philip R. Spradling, Dale J. Hu, and Brian J. McMahon*
- 7 Other Hepadnaviridae (*Avihepadnaviridae* (DHBV) and *Orthohepadnaviridae* (WHV)), 96  
*Stephen A. Locarnini and Michael Roggendorf*
- 8 Molecular variants of hepatitis B surface antigen (HBsAg), 107  
*Seyed Mohammad Jazayeri, Seyed Moayed Alavian, Payam Dindoost, Howard C. Thomas, and Peter Karayiannis*
- 9 Molecular variants of the precore, core, and core promoter regions of hepatitis B virus, and their clinical significance, 127  
*Peter Karayiannis, William F. Carman, and Howard C. Thomas*
- 10 Natural history of chronic hepatitis B virus infection, 143  
*Yun-Fan Liaw*

- 11 Extrahepatic manifestations of hepatitis B infection, 154  
*Christian Trépo, Majid Amiri, and Loïc Guillevin*
- 12 Hepatitis B and hepatocellular carcinoma, 163  
*Marie Annick Buendia and Pierre Tiollais*
- 13 Murine models and human studies of pathogenesis of chronic hepatitis B, 176  
*Juandy Jo, Anthony Tanoto Tan, and Antonio Bertolotti*
- 14 Treatment of hepatitis B, 188  
*Hellan K. Kwon and Anna S.F. Lok*
- 15 Liver transplantation for chronic hepatitis B and C, 203  
*Ed Gane*

## Section IV: Hepatitis C Virus

- 16 Structure and molecular virology, 221  
*Michael J. McGarvey and Michael Houghton*
- 17 Epidemiology and prevention, 246  
*Josep Quer and Juan I. Esteban Mur*
- 18 The immune response to HCV in acute and chronic infection, 266  
*Robert Thimme and Salim I. Khakoo*
- 19 Animal models of hepatitis C virus infection, 280  
*Patrizia Farci and Jens Bukh*
- 20 Extrahepatic manifestations of hepatitis C virus infection, 295  
*Benjamin Maasoumy, Michael P. Manns, and Markus Cornberg*
- 21 Central nervous system complications of hepatitis C virus infection, 310  
*Daniel M. Forton, Simon Taylor-Robinson, Markus Gess, and Howard C. Thomas*
- 22 *In vitro* replication models, 325  
*Volker Lohmann, Sandra Bühler, and Ralf Bartenschlager*
- 23 Natural history of chronic HCV infection and non-invasive assessment of hepatic fibrosis, 341  
*Laurent Castera*
- 24 Hepatitis C and hepatocellular carcinoma, 353  
*Hubert E. Blum*
- 25 Treatment of hepatitis C, 362  
*Christoph Welsch and Stefan Zeuzem*

- 26 Development of anti-HCV drugs, 377  
*Esperance Schaefer and Raymond T. Chung*

### Section V: Hepatitis D Virus

- 27 Structure and molecular virology, 395  
*Francesco Negro*
- 28 Epidemiology and natural history, 403  
*Heiner Wedemeyer, Svenja Hardtke, and Michael P. Manns*
- 29 Treatment of hepatitis D, 410  
*Alessia Ciancio and Mario Rizzetto*

### Section VI: Hepatitis E Virus

- 30 Structure and molecular virology, 419  
*Xiang-jin Meng*
- 31 Epidemiology, experimental models, and prevention: zoonotic aspects of hepatitis E, 431  
*Subrat Kumar Panda and Satya Pavan Kumar Varma*
- 32 Clinical and pathological features, and diagnosis, 442  
*Cyril Sieberhagen and Matthew E. Cramp*

### Section VII: Clinical Aspects of Viral Liver Disease

- 33 Clinical and diagnostic aspects of viral hepatitis, 453  
*Cui Li Lin, Chelsea Q. Xu, and Jack R. Wands*
- 34 Treatment of acute hepatitis, severe acute hepatitis, and acute liver failure, 468  
*Hans L. Tillmann and Alastair D. Smith*

- 35 Hepatitis and hemophilia, 486  
*Mike Makris and Geoffrey Dusheiko*
- 36 Hepatitis in persons infected with HIV, 494  
*Janice Main and Brendan McCarron*
- 37 Migration, hepatitis B, and hepatitis C, 506  
*Manuel Carballo, Rowan Cody, Megan Kelly and Angelos Hatzakis*
- 38 Occupational aspects of hepatitis, 515  
*William L. Irving and Fortune Ncube*
- 39 Neonatal and pediatric infection, 529  
*Deirdre A. Kelly and C.Y. William Tong*
- 40 Management of hepatocellular carcinoma, 544  
*Massimo Iavarone and Massimo Colombo*
- 41 Application of molecular biology to the diagnosis of viral hepatitis, 552  
*Stéphane Chevaliez, Christophe Rodriguez, and Jean-Michel Pawlotsky*
- 42 Disinfection and sterilization, 564  
*Martin S. Favero and Walter W. Bond*
- 43 Evolution of hepatitis viruses, 575  
*Peter Simmonds and Donald B. Smith*

Index, 587

*Colour plate section facing p.372*



# List of Contributors

## **Seyed Moayed Alavian PhD**

Professor of Gastroenterology and  
Hepatology  
Middle East Liver Diseases Center  
(MELD)  
Tehran, Iran

## **Malcolm R. Alison PhD, DSc**

Professor of Stem Cell Biology  
Centre for Tumour Biology  
Barts Cancer Institute  
Barts and The London School of  
Medicine and Dentistry  
London, UK

## **Nadia Amharref PhD**

Postdoctoral Fellow  
Oak Ridge Institute for Science and  
Education (ORISE) Research  
Participation Program  
Center for Biologics Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

## **Majid Amiri MD, PMP, AFSA**

Associate Professor of Medicine  
Service d'Hépatogastroentérologie  
Hôpital de la Croix Rousse  
Hospices Civils de Lyon;  
Centre de Recherche en Cancérologie  
de Lyon  
Lyon, France

## **Ralf Bartenschlager PhD**

Professor of Virology  
Department of Infectious Diseases  
Molecular Virology  
University of Heidelberg  
Heidelberg, Germany

## **Antonio Bertoletti MD**

Director, Infection & Immunity  
Program  
Singapore Institute for Clinical Sciences  
A\*STAR;  
Program of Emerging Viral Diseases  
Duke-NUS Graduate Medical School;  
Department of Medicine  
Yong Loo Lin School of Medicine  
National University of Singapore  
Singapore

## **Hubert E. Blum MD**

Professor of Medicine  
Department of Medicine II  
University Hospital of Freiburg  
Freiburg, Germany

## **Walter W. Bond MS**

Consulting Microbiologist  
RCSA, Inc.  
Lawrenceville, CA, USA

## **Johanna Bruneau PhD**

Postdoctoral Fellow  
University of Massachusetts Medical  
School  
Worcester, MA, USA

## **Marie Annick Buendia PhD**

Directeur de Recherche Emeritus  
INSERM U.785  
Hepatobiliary Center, Paul Brousse  
Hospital  
University Paris-Sud  
Villejuif, France

## **Sandra Bühler PhD**

Scientific Coordinator  
Department of Infectious Diseases  
Molecular Virology  
University of Heidelberg  
Heidelberg, Germany

## **Jens Bukh MD**

Professor  
Copenhagen Hepatitis C Program  
(CO-HEP)  
Department of Infectious Diseases and  
Clinical Research Centre  
Copenhagen University Hospital,  
Hvidovre;  
Department of International Health,  
Immunology and Microbiology  
University of Copenhagen  
Copenhagen, Denmark

## **Manuel Carballo PhD, MPH**

Executive Director  
International Centre for Migration,  
Health and Development  
Geneva, Switzerland

## **William F. Carman MBBCh, MMed(Virology), PhD, FRCPath**

Professor (ret.)  
Fast Track Diagnostics  
Junglinster, Luxembourg

## **Laurent Castera MD, PhD**

Senior Lecturer  
Service d'Hépatologie  
INSERM U733 CRB3  
Université Denis Diderot Paris-VII  
Hôpital Beaujon  
Assistance Publique-Hôpitaux de Paris  
Clichy, France

## **Stéphane Chevaliez PharmD, PhD**

Assistant Professor  
National Reference Center for Viral  
Hepatitis B, C and D  
Department of Virology  
Hôpital Henri Mondor  
Université Paris-Est  
Créteil, France

**Raymond T. Chung MD**

Vice Chief, Gastroenterology  
Director of Hepatology  
Associate Professor of Medicine  
Massachusetts General Hospital  
Boston, MA, USA

**Alessia Ciancio MD, PhD**

Division of Gastroenterology  
University of Torino  
Torino, Italy

**Rowan Cody BA, MPH**

Research Officer  
International Centre for Migration,  
Health and Development  
Geneva, Switzerland

**Massimo Colombo MD**

Professor of Gastroenterology  
A.M. & A. Migliavacca Center for Liver  
Disease  
1st Division of Gastroenterology  
Fondazione IRCCS Ca' Granda  
Maggiore Hospital  
University of Milan  
Milan, Italy

**Markus Cornberg MD**

Consultant Physician  
Department of Gastroenterology,  
Hepatology and Endocrinology  
Hannover Medical School  
Hannover, Germany

**Benjamin Cowie MB BS,  
PhD, FRACP**

Epidemiologist and Physician  
WHO Regional Reference Laboratory  
for Hepatitis B;  
Victorian Infectious Diseases Reference  
Laboratory (VIDRL);  
Victorian Infectious Diseases Service  
Royal Melbourne Hospital;  
Department of Medicine  
University of Melbourne  
Melbourne, VIC, Australia

**Matthew E. Cramp MB BS,  
MD, FRCP**

Consultant Hepatologist and Honorary  
Professor of Hepatology  
South West Liver Unit  
Derriford Hospital;  
Plymouth University Peninsula School of  
Medicine and Dentistry  
Plymouth, UK

**Payam Dindoost MD, PhD**

Professor  
Middle East Liver Diseases Center  
(MELD)  
Tehran, Iran

**Geoffrey Dusheiko MD, MB,  
BCh**

Professor of Medicine  
UCL Institute for Liver and Digestive  
Health  
Royal Free Hospital  
London, UK

**Patrizia Farci MD**

Chief, Hepatic Pathogenesis Section  
Laboratory of Infectious Diseases  
National Institute of Allergy and  
Infectious Diseases (NIAID)  
National Institutes of Health (NIH)  
Bethesda, MD, USA

**Martin S. Favero PhD**

Johnson & Johnson  
Irvine, CA, USA

**Stuart J. Forbes MB, ChB,  
PhD, FRCP(Ed)**

Professor of Transplantation and  
Regenerative Medicine and  
Consultant Hepatologist  
MRC Centre for Regenerative Medicine  
The University of Edinburgh  
Edinburgh, UK

**Daniel M. Forton MB, BS,  
PhD, FRCP**

Consultant Hepatologist and Senior  
Lecturer  
St Georges University of London  
London, UK

**Ed Gane MB, ChB, MD,  
FRACP, MNZM**

Professor and Hepatologist  
New Zealand Liver Transplant Unit  
Auckland City Hospital  
Auckland, New Zealand

**Markus Gess MB, BS, MRCP**

Consultant Gastroenterologist  
Kingston General Hospital  
Surrey, UK

**Loïc Guillevin MD**

Professor of Medicine  
Head of the Department of Internal  
Medicine  
Assistance Publique-Hôpitaux de Paris  
Hôpital Cochin  
Université Paris-Descartes  
Paris, France

**Svenja Hardtke PhD**

Projektmanagement HepNet  
Study-House  
Department of Gastroenterology,  
Hepatology and Endocrinology  
Hannover Medical School  
Hannover, Germany

**Angelos Hatzakis MD, PhD**

Professor of Epidemiology and  
Preventative Medicine  
Director, Department of Hygiene,  
Epidemiology and Medical Statistics  
Athens University Medical School  
Athens, Greece

**Michael Houghton BSc,  
PhD**

Professor  
Department of Medical Microbiology  
and Immunology  
University of Alberta  
Rexall Centre for Health Research  
Edmonton, AB, Canada

**Dale J. Hu MD, MPH**

Director, International Emerging  
Infections Program  
US CDC Office, US Embassy  
Beijing, China

**Massimo Iavarone MD, PhD**

Physician  
A.M. & A. Migliavacca Center for Liver  
Disease  
1st Division of Gastroenterology  
Fondazione IRCCS Ca' Granda  
Maggiore Hospital  
University of Milan  
Milan, Italy

**William L. Irving MA, MB,  
BChir, MRCP, PhD, FRCPATH**

Professor of Virology and Honorary  
Consultant  
Department of Microbiology  
University Hospital  
Queen's Medical Centre  
Nottingham, UK

**Jerome Jacques PhD**

Postdoctoral Fellow  
Oak Ridge Institute for Science and  
Education (ORISE) Research  
Participation Program;  
Center for Biologics Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

**Seyed Mohammad Jazayeri MD, PhD**

Associate Professor  
Hepatitis B Laboratory, Department of  
Virology  
School of Public Health  
Tehran University of Medical Sciences  
Tehran, Iran

**Juandy Jo MD, PhD**

Research Fellow  
Program of Emerging Viral Diseases  
Duke-NUS Graduate Medical School  
Singapore

**Gerardo G. Kaplan PhD**

Senior Investigator  
Center for Biologics Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

**Peter Karayiannis BSc, PhD, FIBMS, FRCPATH(Virology)**

Reader in Molecular Virology  
Hepatology & Gastroenterology Section  
Department of Medicine  
Imperial College London  
London, UK

**Deirdre A. Kelly MD, FRCPI, FRCP, FRCPCH**

Professor of Paediatric Hepatology  
The Liver Unit  
Birmingham Children's Hospital NHS  
Trust  
Birmingham, UK

**Megan Kelly BS, MPH**

MPH Candidate  
Tulane University School of Public  
Health and Tropical Medicine  
New Orleans, LA, USA

**Salim I. Khakoo MD**

Professor of Hepatology  
Director of Biomedical Research (IFLS)  
Faculty of Medicine  
University of Southampton  
Southampton General Hospital  
Southampton, UK

**Krishnamurthy Konduru PhD**

Staff Scientist  
Laboratory of Emerging Pathogens  
Center for Biologics Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

**Hellan K. Kwon MD**

Assistant Professor of Medicine  
Division of Gastroenterology and  
Hepatology  
University of Michigan Health System  
Ann Arbor, MI, USA

**Yun-Fan Liaw MD**

Professor of Medicine  
Liver Research Unit  
Chang Gung Memorial Hospital  
Chang Gung University College of  
Medicine  
Taipei, Taiwan

**Cui Li Lin MD**

Fellow in Gastroenterology and  
Hepatology  
Warren Alpert Medical School of  
Brown University  
Providence, RI, USA

**Stephen A. Locarnini MBBS, BSc(Hons), PhD, FRCPATH**

Head, Research & Molecular  
Development  
Victorian Infectious Diseases Reference  
Laboratory  
Melbourne, VIC, Australia

**Volker Lohmann PhD**

Group Leader  
Department of Infectious Diseases  
Molecular Virology  
University of Heidelberg  
Heidelberg, Germany

**Anna S.F. Lok MD**

Alice Lohrman Andrews Research  
Professor in Hepatology  
Director of Clinical Hepatology  
Professor of Internal Medicine  
Associate Chair for Clinical Research,  
Department of Internal Medicine  
University of Michigan Health System  
Ann Arbor, MI, USA

**Souphalone Luangsay PhD**

Research Associate  
Lyon University  
Cancer Research Center of Lyon  
(CRCL)  
INSERM  
Lyon, France

**Benjamin Maasoumy MD**

Physician and Research Fellow  
Department of Gastroenterology,  
Hepatology and Endocrinology  
Hannover Medical School  
Hannover, Germany

**Janice Main MB ChB FRCP(Edin & Lond)**

Reader and Consultant in Infectious  
Diseases and General Internal  
Medicine  
Department of Medicine  
Imperial College London  
St Mary's Hospital Campus  
London, UK

**Mike Makris MA, MB BS, MD, FRCP, FRCPATH**

Reader in Haemostasis and Thrombosis  
Department of Cardiovascular Science  
University of Sheffield;  
Sheffield Haemophilia and Thrombosis  
Centre  
Royal Hallamshire Hospital  
Sheffield, UK

**Mohanraj Manangeeswaran PhD**

Postdoctoral Fellow  
Oak Ridge Institute for Science and  
Education (ORISE) Research  
Participation Program  
Center for Biologics Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

**Michael P. Manns MD**

Professor and Chairman  
Department of Gastroenterology,  
Hepatology and Endocrinology  
Hannover Medical School  
Hannover, Germany

**Brendan McCarron MBChB, MRCP**

Consultant Physician  
South Tees Hospitals NHS Foundation  
Trust  
Middlesbrough, UK

**Michael J. McGarvey BA, BSc, PhD**

Reader in Molecular Virology  
Department of Medicine  
Faculty of Medicine  
Imperial College London  
St Mary's Hospital Campus  
London, UK

**Brian J McMahon MD, MACP**

Scientific Program and Clinical Director  
Liver Disease and Hepatitis Program  
Alaska Native Tribal Health  
Consortium;  
Guest Researcher  
Arctic Investigations Program  
Centers for Disease Control and  
Prevention  
Anchorage, AK, USA

**Xiang-Jin Meng MD, PhD**

Professor of Molecular Virology  
Center for Molecular Medicine and  
Infectious Diseases  
Department of Biomedical Sciences and  
Pathobiology  
Virginia Polytechnic Institute and State  
University (Virginia Tech)  
Blacksburg, VA, USA

**Juan I. Esteban Mur MD, PhD**

Professor of Medicine  
Liver Unit  
Hospital Universitari Vall d'Hebron  
(HUVH)  
Universitat Autònoma de Barcelona  
CIBERehd Instituto de Salud Carlos III  
Barcelona, Spain

**Siham Nakamura BS**

Postbac Fellow  
Oak Ridge Institute for Science and  
Education (ORISE) Research  
Participation Program  
Center for Biologicals Evaluation and  
Research  
US Food and Drug Administration  
Bethesda, MD, USA

**Fortune Ncube BSc, BMed  
Sci, BM BS, DRCOG, MSc  
PHM, FFPHM, FRIPH**

Consultant Epidemiologist, PHM  
Bloodborne Viruses  
Head of BBV Section  
HIV and Sexually Transmitted  
Infections Department  
Public Health England  
London, UK

**Francesco Negro MD**

Adjunct Professor  
Divisions of Clinical Pathology and  
Gastroenterology and Hepatology  
University Hospital  
Geneva, Switzerland

**Subrat Kumar Panda MD,  
FASc, FNA, FAMS, JC Bose  
National Fellow**

Professor and Head of Pathology  
All India Institute of Medical Sciences  
Ansari Nagar, New Delhi, India

**Jean-Michel Pawlotsky MD,  
PhD**

Director, National Reference Center for  
Viral Hepatitis B, C and D  
Chief, Department of Biology  
Head, Department of Virology,  
Bacteriology, and Hygiene  
Head, Research Team "Pathophysiology  
and Therapy of Chronic Viral  
Hepatitis"  
Hôpital Henri Mondor  
Université Paris-Est  
Créteil, France

**Josep Quer PhD**

Senior Researcher  
Liver Unit, Laboratori Malalties  
Hepàtiques  
Vall d'Hebron Institut de Recerca  
(VHIR)  
Hospital Universitari Vall d'Hebron  
(HUVH)  
Universitat Autònoma de Barcelona  
CIBERehd Instituto de Salud Carlos III  
Barcelona, Spain

**Mario Rizzetto MD**

Professor of Gastroenterology  
Molinette Hospital  
Torino, Italy

**Christophe Rodriguez  
PharmD, PhD**

Fellow  
National Reference Center for Viral  
Hepatitis B, C and D  
Department of Virology  
Hôpital Henri Mondor  
Université Paris-Est  
Créteil, France

**Michael Roggendorf Prof.  
Dr.med.**

Director (Emeritus)  
Institute for Virology  
University Hospital of Essen  
University of Duisburg-Essen  
Essen, Germany

**Esperance Schaefer MD,  
MPH**

Instructor in Medicine  
Gastroenterology Unit  
Massachusetts General Hospital  
Harvard Medical School  
Boston, MA, USA

**Cyril Sieberhagen MB, ChB,  
MRCP(UK)**

Clinical Research Fellow  
South West Liver Unit  
Derriford Hospital;  
Plymouth University Peninsula School of  
Medicine and Dentistry  
Plymouth, UK

**Peter Simmonds BM, PhD,  
FRCPath**

Infection and Immunity Division  
The Roslin Institute  
University of Edinburgh  
Edinburgh, UK

**Alastair D. Smith MB, ChB**

Associated Professor  
Division of Gastroenterology  
Duke University  
Durham, NC, USA

**Donald B. Smith BSc, PhD**

Postdoctoral Scientist  
Centre for Immunity, Infection and  
Evolution  
Ashworth Laboratories  
University of Edinburgh  
Edinburgh, UK

**Philip R. Spradling, MD**

Medical Epidemiologist  
Division of Viral Hepatitis  
Centers for Disease Control and  
Prevention  
Atlanta, GA, USA

**Gyongyi Szabo MD, PhD**

Professor  
Associate Dean for Clinical and  
Translational Sciences  
Vice Chair for Research  
Department of Medicine  
University of Massachusetts Medical  
School  
Worcester, MA, USA

**Anthony Tanoto Tan PhD**

Research Fellow  
Program of Emerging Viral Diseases  
Duke-NUS Graduate Medical School  
Singapore

**Simon Taylor-Robinson MD  
FRCP**

Professor in Translational Medicine  
Clinical Dean  
Department of Medicine  
Imperial College London  
St Mary's Hospital Campus  
London, UK

**Robert Thimme MD**

Heisenberg Professor for Hepatology  
Leading Attending  
Department of Medicine II  
University Medical Center Freiburg  
Freiburg, Germany

**Howard C. Thomas BSc,  
PhD, FRCP, FRCPath,  
FMedSci**

Emeritus Professor of Hepatology  
Department of Medicine  
Imperial College London  
London, UK

**Hans L. Tillmann MD**

Associate Professor  
Duke Clinical Research Institute and  
Division of Gastroenterology  
Duke University  
Durham, NC, USA

**Pierre Tiollais MD**

Professor  
Unite d'Organisation Nucleaire et  
Oncogenese  
INSERM U.579  
Institut Pasteur  
Paris, France

**C.Y. William Tong MD,  
FRCP, FRCPath**

Consultant Virologist and Honorary  
Senior Lecturer  
Department of Infectious Diseases  
Guy's and St Thomas' NHS Foundation  
Trust;  
King's College London School of  
Medicine  
London, UK

**Christian Trépo MD, PhD**

Professor  
Service d'Hépatogastroentérologie  
Hôpital de la Croix Rousse  
Hospices Civils de Lyon;  
Centre de Recherche en Cancérologie  
de Lyon  
Lyon, France

**Satya Pavan Kumar Varma  
PhD**

Research Officer  
Department of Pathology  
All India Institute of Medical Sciences  
Ansari Nagar, New Delhi, India

**Jack R. Wands MD**

Jeffrey and Kimberly Greenberg-  
Artemis and Martha Joukowsky  
Professor in Gastroenterology and  
Medical Science  
Director, Division of Gastroenterology  
and Hepatology and the Liver  
Research Center  
Warren Alpert Medical School of  
Brown University  
Providence, RI, USA

**Heiner Wedemeyer MD**

Professor  
Department of Gastroenterology,  
Hepatology and Endocrinology  
Hannover Medical School  
Hannover, Germany

**Christoph Welsch MD**

Senior Research Fellow  
Department of Internal Medicine I  
J.W. Goethe University Hospital  
Frankfurt am Main, Germany

**Chelsea Q. Xu BS**

Research Associate  
The Liver Research Center/Rhode  
Island Hospital  
Warren Alpert Medical School of  
Brown University  
Providence, RI, USA

**Stefan Zeuzem MD**

Professor of Medicine  
Chief, Department of Internal  
Medicine I  
J.W. Goethe University Hospital  
Frankfurt am Main, Germany

**Fabien Zoulim MD, PhD**

Professor of Medicine  
Head of Hepatology Department  
Hospices Civils de Lyon;  
Head of Viral Hepatitis Research Team  
Lyon University  
Cancer Research Center of Lyon  
(CRCL)  
INSERM  
Lyon, France

**Arie J. Zuckerman MD,  
DSc, FRCP, FRCPath,  
FMedSci**

Emeritus Professor of Medical  
Microbiology  
Formerly Principal and Dean  
Royal Free Hospital School of  
Medicine, and later  
Royal Free and University College  
Medical School  
University College London  
London, UK



# Preface

Viral hepatitis remains a major public health problem throughout the world. Hepatitis A virus infects 1–90% or more of the human population, and it varies according to the socioeconomic, sanitary, and public health infrastructure of each country. Hepatitis B virus has infected one-third of the world population, with between 350 and 400 million carriers of the virus, many of whom progress to chronic liver disease and hepatocellular carcinoma. Hepatitis C virus is estimated to have infected 150–200 million people (probably a gross underestimate), with about 80% infected persistently, and this leads to serious sequelae including primary liver cancer. Infection with hepatitis D virus also occurs throughout the world and is hyperendemic in some countries, and hepatitis E is common and epidemic in a number of non-industrialized regions, with increasing evidence of zoonotic spread and sporadic infection in many countries.

Progress on all aspects of viral hepatitis is remarkably rapid, with many thousands of published accounts of original studies, and the mountain of new information is often bewildering and may be difficult to access. The pressing need for a fourth edition became clear, and the text has been revised and updated. The chapter

on the history of hepatitis has been omitted (which is somewhat unfortunate because the future evolves from the past) in order to provide space for several new topics.

The fourth edition of *Viral Hepatitis* is designed to include a balanced and carefully distilled account of the more recent advances in this field written by a constellation of internationally recognized experts from many countries. We acknowledge their outstanding contributions, including those made by our two new co-editors, Professor Anna Lok and Professor Stephen Locarnini.

We hope that the book will prove useful to virologists, immunologists, specialists in infectious diseases, hepatologists, gastroenterologists, and, of course, public health and occupational health physicians and aspiring scientists. It is a book for those addressing the management and prevention of an important common infection and its associated liver diseases, which affect a large proportion of the world's population.

**Howard C. Thomas  
and  
Arie J. Zuckerman**

## **Section I**

# **Introduction to Liver Biology**



# Chapter 1

## Liver regeneration and fibrosis

Stuart J. Forbes<sup>1</sup> and Malcolm R. Alison<sup>2</sup>

<sup>1</sup>MRC Centre for Regenerative Medicine, The University of Edinburgh, Edinburgh, UK

<sup>2</sup>Centre for Tumour Biology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, London, UK

### Summary

In a healthy adult liver, the rate of cell turnover is very low. Following acute liver injury, restoration of parenchymal mass is achieved by proliferation of normally mitotically quiescent hepatocytes. However, chronic liver injury results in the loss of this proliferative capacity of the hepatocytes, as increasing numbers of cells become senescent. In this situation, there is activation of hepatic progenitor cells (HPCs) from within the intrahepatic biliary tree. These bipotential cells are capable of supplying biliary cells and hepatocytes. In animal models, there is some controversy regarding the relative contribution to parenchymal regeneration from these two compartments, but human studies are compatible with the suggestion that as the severity and chronicity of the liver injury increase, immature progenitor cells contribute more to regeneration than mature hepatocytes. We are now beginning to understand the molecular signals and niche requirements that govern their cell fate. Alongside the parenchymal regeneration in chronic liver injury, there is a stereotypical wound-healing response with activation of hepatic stellate cells (HSCs) into scar-forming myofibroblasts and deposition of collagen. This change in the extracellular matrix (ECM) affects the regenerative capacity of the liver, and excess scar tissue can impair liver regeneration from either hepatocytes or HPCs.

### Introduction

Normally the liver has a low level of hepatocyte turnover, but in response to modest hepatocyte loss, a rapid regenerative response occurs from all cell types in the liver to restore organ homeostasis (comprehensively reviewed in [1, 2]). More severe liver injury, particularly chronic repetitive injury (e.g., chronic viral hepatitis), is often associated with hepatocyte replicative senescence. This activates facultative stem cells of biliary origin that give rise to cords (the “ductular reaction”) of bipotential transit-amplifying cells (named oval cells [OCs] in

rodents and HPCs in humans) that can differentiate into either hepatocytes or cholangiocytes. Moreover, the major primary tumors of the liver (hepatocellular carcinoma [HCC] and cholangiocarcinoma [CC]) invariably arise in a setting of chronic inflammation that is accompanied by both hepatocyte regeneration and ductular reactions, and while it seems that the founder cell of CCs is a proliferating cholangiocyte, the morphological heterogeneity often observed in HCCs suggests that these tumors can arise from bipotential HPCs as well as more mature hepatocytes. HCCs also appear to possess subpopulations of cancer stem cells, which are responsible

for continued tumor propagation and metastasis, and a number of phenotypic markers have been proposed for their identification.


## Liver turnover and regeneration

### Kinetic organization

The healthy liver in adults is mitotically quiescent with levels of proliferation suggesting a turnover time for hepatocytes in excess of a year. Nevertheless, there is still considerable debate as to how the liver is organized. Most studies concur that hepatic stem cells are located in the periportal region; for example, in the mouse, bromodeoxyuridine (BrdU) pulse-chase analysis following two rounds of acetaminophen intoxication has observed so-called label-retaining cells (LRCs), considered to be slowly dividing progenitor cells, as both interlobular cholangiocytes and peribiliary hepatocytes [2].

In humans, EpCAM<sup>+</sup>NCAM<sup>+</sup> cells in the periportal located canals of Hering have been identified as putative HPCs and it is suggested that there are eight maturational lineage stages moving from the periportal (progenitor) region to the perivenous region.


An important question remains: is the liver organized like the intestine, with a unidirectional flux of cells that are “born” in the portal area and migrate along a trajectory leading to the hepatic veins? This so-called streaming liver hypothesis was first advocated by Gershom Zajicek and colleagues (reviewed in [2]); examining the location of labeled hepatocytes in intact adult rat livers over time after a single injection of tritiated thymidine, they suggested that hepatocytes moved at a speed of over 2 μm/day from the periportal region to the central vein. A recent murine study by Furuyama and colleagues [3] (reviewed in [4]) appears to support the idea that hepatocytes migrate centrifugally from portal areas (Figure 1.1). They examined the expression of the embry-



**Figure 1.1** Top: Strategy of the genetic lineage-tracing study employed by Furuyama *et al.* [3] using tamoxifen-induced Cre-mediated cell tracking using Sox9IRES-CreERT2; Rosa26R mice. Bottom: Schematic illustrating the spread of X-gal staining after 8-week-old mice were injected with tamoxifen. After one day, only intrahepatic bile duct cells are

labeled, but later X-gal-positive hepatocytes gradually spread from the portal tracts to the central veins, thus supporting the streaming liver hypothesis. See Alison and Lin [4] for further details. (Source: Alison and Lin. *Hepatology* 2011, 53: 1393–1396 [4]). (Color plate 1.1)





**Figure 1.2** (A) A single cytochrome c oxidase (CCO)-deficient patch, appearing to emanate from the portal tract. (B) High-power magnification illustrates that within the patch there are CCO-positive sinusoid-lining cells (asterisks) indicative of different cells of origin from hepatocytes. See Fellous *et al.* [7] for further details. (Source: Fellous TG *et al.* *Hepatology* 2009, 49: 1655–1663 [7]). (Color plate 1.2)

onic transcription factor Sox9 in the liver. In human liver, immunohistochemistry identified interlobular bile duct cells as Sox9-expressing cells, and a similar pattern was seen in adult mice when a reporter gene, either enhanced GFP or LacZ, was knocked into the *Sox9* locus. Adopting tamoxifen-inducible genetic lineage tracing from the *Sox9* locus, detecting Sox9-lineage cells by X-gal staining, Furuyama *et al.* [3] found that X-gal positivity spread out from the portal areas toward the hepatic veins until the majority of hepatocytes were labeled within 8–12 months. Thus, the paper suggested that indeed cells “streamed,” but more importantly hepatic replacement was from cytokeratin 7 (CK7)-Sox9-positive biliary cells, identifying cells within the biliary tree as drivers not only of hepatocyte replacement when regeneration from existing hepatocytes is compromised (discussed further in this chapter) but also of normal hepatocyte turnover. However, there is controversy as other studies of mice have failed to find evidence for the normal liver parenchyma being “fed” from the biliary system. Carpentier *et al.* [5] also employed lineage labeling in mice, this time from Sox9-expressing ductal plate cells in late embryonic development (E15.5), finding that these cells gave rise to interlobular bile ducts, canals of Hering, and periportal hepatocytes, and that liver homeostasis did not require a continuous supply of cells from Sox9 progenitors. Iverson *et al.* [6] have sought to quantify the dynamics of mouse liver turnover by lineage labeling following activation of an albumin-*Cre* transgene, calculating that 0.076% of hepatocytes had differentiated from albumin-naïve cells over a 4-day period.

In human liver, Fellous *et al.* [7] have identified clonal populations of hepatocytes based upon finding large patches of cells deficient in the mitochondrial DNA

(mtDNA)-encoded cytochrome c oxidase (CCO) enzyme, all sharing an identical neutral mutation in the CCO gene indicating derivation from a single cell. Significantly, these CCO-deficient patches were all connected to portal areas and had a portal vein-to-hepatic vein orientation (Figure 1.2), suggesting a “streaming” nature but without providing information of whether they are derived from a periportal progenitor cell or an interlobular biliary cell.

### Liver regeneration

The regenerative capacity of the liver is impressively demonstrated when two-thirds of the rat liver is surgically removed (a 2/3 partial hepatectomy, or 2/3 PH) and the residual liver then undergoes waves of hyperplasia and hypertrophy to restore preoperative liver mass within about 10 days [1, 2]. After a 2/3 PH in healthy adult rats, all the normally proliferatively quiescent hepatocytes leave  $G_0$  to semisynchronously enter the cell cycle. DNA synthesis is first initiated in the periportal hepatocytes at about 15 hours after PH, with a peak in the hepatocyte DNA synthesis labeling index of ~40% at 24 hours. Midzonal and centrilobular hepatocytes enter DNA synthesis at progressively later times, but the hyperplastic response in hepatocytes is essentially complete by 96 hours, to be followed by a phase of hepatocyte hypertrophy. Elegant labeling studies have identified three groups of regenerative hepatocytes in mice, with all cells dividing at least once, but with the periportal hepatocytes that divide first dividing maybe three or more times after PH.

As might be expected, age has an adverse effect on the response; in old rats (>2 years old), a significant number of hepatocytes do not proliferate after PH,

seemingly becoming reproductively senescent. To maintain liver homeostasis, the nonparenchymal cells (cholangiocytes and endothelial cells) must also expand their numbers, and their cell cycle entry is delayed a few hours behind that of hepatocytes [2].

### Molecular regulation of liver regeneration

Numerous cytokines, growth factors, and signaling pathways have been implicated in (1) the initiation (priming) of hepatocytes in order to be responsive to liver mitogens, (2) the proliferative response itself, and (3) the curtailment of the response. The “priming phase” in the first few hours after PH, which is probably instrumental in the G<sub>0</sub> to G<sub>1</sub> transition, is associated with the upregulation of many genes not expressed in the normal liver and is essentially cytokine driven [2], with activation of transcription factors such as activator protein 1 (AP1), nuclear factor kappa-light-chain-enhancer of activated B (NF-κB), and signal transducer and activator of transcription 3 (STAT3) being particularly important. The ultimate cause of cytokine accumulation is unclear, but enteric lipopolysaccharides may be the master regulator of the innate immune response, and liver injury can be associated with a defective intestinal barrier leading to exposure to lipopolysaccharides and complement fragments. Such exposure activates the NF-κB pathway in Kupffer cells, resulting in the production and secretion of interleukin 6 (IL6) that activates the JAK/STAT pathway, leading to the initiation of DNA synthesis in hepatocytes. In mice, complement activation (in particular, C3a and C5a) leads to the recruitment of natural killer T (NKT) cells and the production of IL4 by these cells [8]. IL-4 maintains IgM levels and deposition in the liver, leading to increased C3a and C5a accumulation that in turn stimulates liver macrophages to produce IL6. The cytokine interleukin 1 receptor antagonist (IL1ra) is also important in the early phase of regeneration, reducing inflammatory stress and thus promoting proliferation [9].

The proliferative response itself appears to be driven by a number of growth factors and signaling pathways, including IL6, tumor necrosis factor alpha (TNFα), hepatocyte growth factor (HGF), amphiregulin, stem cell factor (SCF), insulin-like growth factor 1 (IGF1), T3, bone morphogenetic protein 7 (BMP7), Wnt, β-catenin, Hedgehog (Hh), and phosphoinositide-3 kinase (PI3K), although no one factor or pathway appears crucial to the process [2]. Some of these signals are autocrine, and others are paracrine; for example, in mice sinusoidal endothelial cells are involved in hepatocyte regeneration with vascular endothelial growth factor receptor (VEGFR)-dependent upregulation of the transcription factor Id1 leading to the release of hepatotrophic factors

such as Wnt2 and HGF [10, 11]. Moreover, it seems that endothelial progenitor cells recruited from the bone marrow after PH provide the richest source of HGF [11]. Hepatic stellate cells (HSCs) also support liver regeneration and are activated by massive upregulation of delta-like 1 homology (Dlk1) that represses *Pparγ* in stellate cells [12]. Regenerative competence in mouse and human also appears to be maintained by activation of telomerase activity in regenerating hepatocytes [13]. Micro-RNAs (miRs) are also involved in regeneration after PH; for example, in mice there is upregulation of miR-21 in the priming phase that targets a proliferation inhibitor facilitating cyclin D1 translation, and downregulation of miR-378 that targets *odc1* messenger RNA (mRNA), ornithine decarboxylase activity being essential for DNA synthesis [14]. In rats after PH, there are also dramatic changes in miRs, with upregulation of 40% of investigated miRs in the priming phase and downregulation of 70% of miRs at 24 hours after PH, presumably facilitating maximal proliferation [15].

Equally important are the molecular mechanisms that curtail the regenerative response, ensuring the liver does not overcompensate for lost mass. Transforming growth factor beta (TGFβ) produced by stellate cells inhibits hepatocyte replication, and several mechanisms are involved in its production. In mice, serotonin acts on 5-HT<sub>2B</sub> receptors in stellate cells, leading to phosphorylation of JunD via ERK, resulting in recruitment of JunD to AP1 binding sites in the promoter region of the *tgfb1* gene [16]. The multidomain matrix glycoprotein thrombospondin-1 (Tsp1) is also involved in TGFβ1 production in mice; Tsp1 is expressed by endothelial cells in response to reactive oxygen species (ROS) shortly after PH and binds to latent TGFβ1 complexes, converting them to active TGFβ1 [17]. The IL6 response is negatively regulated through transcriptional upregulation of suppressor of cytokine signaling 3 (SOCS3), but SOCS3 is not crucial for curtailing proliferation, for although SOCS3 knockout mice have higher levels of hepatocyte proliferation after PH than wild-type mice and restore preoperative liver weight 2 days earlier, proliferation stops after 4 days and liver weight does not go above normal [18]. The Hippo pathway seems particularly important for curtailing liver size; the kinases Mst1 and Mst2 (the mammalian orthologs of *Drosophila* Hippo) are responsible for phosphorylating the Yes-associated protein (Yap) at Ser127, the mammalian ortholog of *Drosophila* Yorkie, which is a transcriptional activator of cell cycle proteins such as Ki-67 and c-Myc – phosphorylation blocks its ability to translocate to the nucleus [19]. Thus, overexpression of Yap in mice leads to massive liver weight increases (25% of body weight versus 5% normally) [20], and likewise Mst1 and Mst2 double knockouts also have massive livers and eventually develop HCC [21, 22].

### A second tier of regeneration: oval cells and HPCs

Massive acute liver injury, chronic liver injury, or large-scale hepatocyte senescence results in the activation of a reserve or potential progenitor cell compartment located within the intrahepatic biliary system [1, 2]. Replicative senescence can occur in conditions such as chronic hepatitis and fatty liver disease [23]. In humans and mice, the extent of the HPC response is proportional to the degree of parenchymal damage [24, 25]. HPCs are derived from interlobular biliary cells and/or the canal of Hering, and in human liver the canal of Hering extends beyond the limiting plate, even perhaps throughout the proximate third of the lobule [26].

A number of animal models have been described to activate this progenitor response. In rats, a very effective model has been to pretreat the animals with 2-acetylaminofluorene (2-AAF) before performing a 2/3 PH (the 2-AAF/PH protocol) [27]. 2-AAF is metabolized by the hepatocyte's cytochrome P450 (CYP450) system, producing metabolites that form DNA adducts, thus preventing hepatocytes from entering the cell cycle in response to PH. Under these constraints, oval cells or HPCs are activated since they lack the CYP enzymes necessary for 2-AAF metabolism. In the mouse, dietary regimes are often employed including a choline-deficient, ethionine-supplemented diet (the CDE diet) that inflicts hepatocyte damage, or a 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) regime that damages cholangiocytes [28]. An oval cell response is also seen when hepatitis B surface antigen (HBsAg-tg) mice (a model of chronic liver injury) are treated with retrorsine, a pyrrolizidine alkaloid that blocks hepatocyte regeneration. This effectively abolishes hepatocyte turnover, resulting in massive oval cell-driven regeneration [29]. The exact location of stem and progenitor cells within the biliary tree is unclear, and it is also unclear if all cells in small-caliber biliary ducts and canals of Hering are capable of giving rise to oval cells, but in the mouse a small subset (3–4%) of antigenically defined biliary cells that express Sox9 give rise to most oval cells in the DDC model [30].

A wide range of markers have been used to identify oval cells and HPCs (Table 1.1) [31]. Many factors, often produced by cells of a hepatic niche that intimately accompanies the reaction, can influence the oval cell–HPC response. Autocrine and paracrine Wnt signaling is clearly involved in the oval cell or HPC response in mice [28, 32], rats [33], and humans [28, 34, 35]. In the rat 2-AAF/PH model, oval cells display nuclear  $\beta$ -catenin and Wnt1 is essential for differentiation of oval cells to hepatocytes; exposure to Wnt1 small hairpin RNA (shRNA) blocked this differentiation, and oval cells generated an atypical ductular reaction – perhaps as the default position [35]. As oval cells and HPCs are

**Table 1.1** Some of the markers used in the identification of oval cells and HPCs in the damaged mammalian liver.

A6 antigen (mouse marker)
ABCG2/BCRP1 (breast cancer resistance protein)
AFP (alpha fetoprotein)
Cadherin 22
CD24 and CD133
Chromogranin A
CK7 and CK19
c-Kit (CD117)
Claudin7
Connexin 43
Dlk1 (Delta-like protein 1)
DMBT1 (deleted in malignant brain tumor 1)
E-cadherin
EpCAM/TROP1 (epithelial cell adhesion molecule)
flt-3 ligand/flt-3
Fn14 (fibroblast-inducible factor 14-kDa protein; TWEAK receptor)
GGT (gamma-glutamyltranspeptidase)
GST-P (placental form of glutathione-S-transferase)
M2-PK (muscle type pyruvate kinase)
NCAM-1/CD56 (neural cell adhesion molecule-1)
PTHrP (parathyroid hormone related peptide)
TACSTD/TROP2 (tumor-associated calcium signal transducer)

*Note:* Many of these markers are also expressed on normal biliary epithelial cells.

bipotential, what regulates whether they become hepatocytes or cholangiocytes? Boulter and colleagues have described the mechanisms in mice governing these critical cell fate decisions [28]. After biliary cell damage with DDC, the intimate association of myofibroblasts with HPCs facilitated Notch signaling ensuring biliary differentiation in oval cells, in essence recapitulating ontogeny. On the other hand, after hepatocyte damage with the CDE diet, adjacent macrophages in response to engulfing hepatocyte debris were involved in Wnt signaling to HPCs that not only turned off Notch signaling but also specified hepatocytic differentiation in oval cells. On the other hand, in the rat 2-AAF/PH model, Notch1 may be important for hepatocytic differentiation since exposure to a  $\gamma$ -secretase inhibitor delayed the maturation process [36]. HGF signaling is also important for the oval cell response: genetic deletion of *c-met* from oval cells in the DDC model results in a diminished response with decreased hepatocytic differentiation [37]. Moreover, a failure to express stromal cell-derived factor 1 (SDF1) leads to less recruitment of macrophages and associated matrix metalloproteinase 9 (MMP9) secretion that is crucial for oval cell migration and liver remodeling (discussed further in this chapter). Hh signaling is another important pathway, and ligands acting through the receptor Patched (Ptc) on murine oval cells and human HPCs are required for progenitor cell survival [38]. Perhaps most



significantly, inflammatory cells produce a range of cytokines and chemokines that initiate the response [2, 32]; SDF1 attracts CXCR4<sup>+</sup> T cells, and these cells express TWEAK (TNF-like weak inducer of apoptosis) that stimulates oval cell proliferation by engaging its receptor Fn14, a 14kDa transmembrane receptor [39]. Tirnitz-Parker and colleagues employed the CDE diet and found that expression of Fn14 is markedly elevated [40]. Fn14 is not a receptor tyrosine kinase, but rather ligand occupancy activates NF- $\kappa$ B signaling as shown by the presence of active (nuclear) NF- $\kappa$ B in a progenitor cell line upon TWEAK stimulation. The early oval cell response to the CDE diet was delayed in Fn14 knockout mice, although interestingly there were comparable numbers of oval cells in wild-type and knockout mice after 3 weeks on the CDE diet. Significantly, recombinant human TWEAK (rhTWEAK) directly stimulated the *in vitro* proliferation of a progenitor cell line in a dose-dependent manner. Other components of the inflammatory response that can stimulate oval cells include lymphotoxin- $\beta$ , interferon alpha (IFN $\alpha$ ), TNF $\alpha$ , and histamine [41]. Resistance to the growth inhibitory effects of TGF $\beta$  may allow oval cells to proliferate under conditions inhibitory to hepatocytes [42].


In terms of negative regulators of the oval cell response, the neurofibromatosis type 2 (*Nf2*) gene product Merlin appears critically important [43]. Genetic deletion of *Nf2* leads to massive oval cell expansion and the development of CC and HCC; Merlin appears to control the availability of epidermal growth factor receptor (EGFR) and other growth factor receptors. Progenitor cells reside in a specialized supportive microenvironment known as a niche; not only do oval cells and HPCs have such a niche but also this niche seems to migrate hand-in-hand with the expansion of oval cells. For example, with the CDE diet the activation of stellate cells (upregulation of alpha smooth muscle actin [ $\alpha$ SMA] expression) and deposition of collagen precede the oval cell response, suggesting that the extension of the niche is a prerequisite for oval cell expansion [44]. In fact, mouse and rat models of oval cell activation and HPC reactions in humans bear a striking similarity, in terms of both the deposition of ECM (particularly laminin) and cells (macrophages and  $\alpha$ SMA<sup>+</sup> myofibroblasts) that accompany progenitor reactions suggestive of a stereotypical niche [45]. Further support for the idea that the ECM adjacent to oval cell reactions is not merely a passive bystander comes from studies of the oval cell reaction in mice that produce mutated collagen I that is highly resistant to MMP degradation [46]; here, a failure to remodel collagen stunts the reaction, seemingly through a failure to establish a laminin-rich progenitor niche. In the 2-AAF/PH model, blocking the activation of stellate cells with L-cysteine was a potent suppressor of the oval cell response, probably related to loss of

cytokines such as TGF $\beta$ 1 and the fibronectin matrix that, among other properties, can concentrate cytokines such as connective tissue growth factor (CTGF) for which oval cells have receptors [47].

Chronic viral hepatitis is, of course, invariably associated with cirrhosis and hepatocyte senescence [48–50], thus activation of HPCs in this setting is common. In the fibrous septae that surround regenerative nodules (RNs), differentiation of CK19-positive HPCs to form buds of intraseptal hepatocytes (ISHs) is often observed [51]. In cirrhosis we observed that RNs are invariably clonally derived (Figure 1.3), suggesting that they are not simply created by fibrotic dissection of the preexisting parenchyma; moreover, they are clonally related to the abutting HPCs (Figure 1.3), and thus have been derived from them [52]. Thus RNs may well represent the further expansion of buds of ISHs.

### Stem cells and liver cancer (founders and propagators)

Whereas CCs are believed to arise from either established biliary ducts or HPCs, the origin of HCCs is more problematic. Clearly hepatocytes are the cell of origin of many HCCs in experimental models where tumor yield is directly related to hepatocyte proliferation or where oncogenic transgenes are driven by the albumin promoter. On the other hand, HPC activation is commonly seen in models of hepatocarcinogenesis and invariably accompanies chronic liver damage in humans, thus making it quite likely that HPCs are the founder cells of many HCCs [53]. An origin of HCCs from HPCs is often suggested because many HCCs contain an admixture of mature hepatocyte-like cells and cells resembling HPCs [1]. If tumors do arise from HPCs, then this indicates a block in HPC differentiation, a process that has been termed “stem cell maturation arrest” [54]. This hypothesis is supported by the fact that murine HCCs induced by a CDE diet have a mixture of neoplastic phenotypes recapitulating stages in normal development, suggesting intermediate states between bipotent oval cells and hepatocytes [55]. Likewise in humans, four prognostic HCC subtypes have been identified equating to liver cell maturational steps [56]. The poorest prognostic groups had a significant proportion of either EpCAM<sup>+</sup>AFP<sup>+</sup> cells (hepatoblast-like) or EpCAM<sup>-</sup>AFP<sup>+</sup> cells (HPC-like), whereas those with EpCAM<sup>+</sup>AFP<sup>-</sup> cells (mature hepatocyte-like) or EpCAM<sup>+</sup>AFP<sup>-</sup> cells (cholangiocyte-like) had a better prognosis. Gene expression profiling has identified a subset of HCCs with a profile consistent with an origin from HPCs, and these patients have a poor prognosis [57]; moreover, counting of CK19-positive cells in HCC can identify a poor-prognosis group [58] that may be related to an enhanced epithelial-mesenchymal transition (EMT) [59].



**Figure 1.3** Mitochondrial DNA genotyping indicates that regenerative nodules can be derived from CK19-positive HPCs. (A) An entirely CCO-deficient nodule (stained blue for succinate dehydrogenase activity). (B) Five groups of cells (1–5) from the same CCO-deficient nodule; cells (6) from the adjacent CCO-deficient ductular reaction, confirmed by CK19 IHC on the next serial section (C, brown staining), and cells (7) from the CCO-positive nodule were laser capture-microdissected, and the entire mitochondrial genome was sequenced. (D) Cell areas 1–5 all contained four different

transition mutations: 2145G>A, 2269G>A, 12362C>T, and 15671A>G (black arrows). (E) Cell area 6 from the abutting CCO-deficient ductular reaction had exactly the same mutations. Heteroplasmy was detected at locations 2145 and 2269 (arrowheads), while the mutations at locations 12362 and 15671 were homoplasmic (black arrows). (F) Cell area 7 from the CCO-positive nodule had no mutation (white arrows). See Lin *et al.* [52] for further details. (Source: Lin WR. *et al.* Hepatology 2010, 51: 1017–1026 [52]). (Color plate 1.3)

A detailed discussion of cancer stem cells (CSCs) in HCC is beyond the scope of this chapter, but a number of phenotypic markers have been proposed for their isolation including CD13, CD90, CD133, ALDH activity, and the side population [60]. As in other organs, HCC CSCs seem relatively resistant to therapy, and strategies to either reduce ABC transporter function [61–63] or induce differentiation [64] have increased CSC sensitivity. For a detailed discussion, see [65].


## Liver fibrosis

Whatever the mode of chronic liver injury, a stereotypical wound-healing response occurs that results in a series of cellular and extracellular matrix changes, an increase in collagen deposition, and a disturbance in the liver architecture. In its extreme form, this results in the development of cirrhosis with gross architectural disturbance, nodule formation, heavy scarring, and vascular

changes, eventually resulting in liver failure or the development of HCC.

Following liver injury there are a number of cellular responses that are key to the fibrotic response, including hepatocyte injury, and hepatic macrophages and endothelial cells are activated [66]. The cells that are primarily responsible for the deposition of ECM are the  $\alpha$ SMA-positive myofibroblasts that are formed principally from the activation of the HSCs. Hepatic myofibroblasts are proliferative and contractile cells that directly secrete collagen matrix, and they have several important paracrine mechanisms that increase the profibrotic environment. Proliferation of hepatic myofibroblasts is stimulated by a number of mitogens, including platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), angiotensin II, VEGF, and thrombin. PDGF is a very potent mitogenic stimulus and is released by activated Kupffer cells, sinusoidal endothelial cells, platelets, and activated myofibroblasts





**Figure 1.4** During liver injury the hepatic macrophages help, along with other factors, to stimulate quiescent fat-storing hepatic stellate cells (HSCs) into activated hepatic myofibroblasts (HMFs). The activated HMFs deposit collagen scar and secrete tissue inhibitors of metalloproteinases (TIMPs), which inhibit the degraders of scar matrix, the matrix metalloproteinases (MMPs). If the cause of liver

injury is removed (e.g., viral eradication), then a recovery phase commences and, to a variable degree, the quantity of liver fibrosis lessens. In this phase, HMFs reduce their TIMP secretion, and the hepatic macrophages secrete MMPs that aid the degradation of scar and promote the apoptosis of HMFs. (Color plate 1.4)

in an autocrine manner. Importantly, myofibroblasts also secrete tissue inhibitors of metalloproteinases (TIMPs).

There has been increasing recognition that wound healing is a dynamic process involving both matrix deposition and degradation, and the balance between the factors that promote scar deposition and those that promote resolution determines the eventual degree of fibrosis within the liver. In this regard, during the formation of fibrosis there is a high level of TIMP in the liver and lower levels of MMPs. This balance reverses with the cessation of liver injury when there is active remodeling of the scar tissue in the liver. HSCs express TIMPs, which results in inhibition of matrix-degrading MMP activity. Therefore, HSCs and myofibroblasts affect the balance of matrix secretion and degradation to favor the accumulation of scar, and they are direct secretors of collagen matrix.

The hepatic macrophages are important orchestrators of the wound-healing response in the liver; they phagocytose apoptotic debris, signal to the HSCs and myofibroblasts, and secrete enzymes capable of matrix degradation. During chronic liver injury, the hepatic macrophages signal to the myofibroblasts via the secretion of TGFβ1 to promote scar deposition. Conversely, following the cessation of liver injury, when there is an active reduction in the number of activated myofibroblasts and fibrosis, the hepatic macrophages are important in promoting the degradation of scar tissue (see Figure 1.4). As mentioned in this chapter, both the myofibroblasts and hepatic macrophages are also important in the liver's regenerative response, underlining how the liver's wound response (fibrosis and its resolution) is closely linked to the epithelial regenerative response. Indeed, experimental studies have shown that

the degradation of collagen scar matrix is required to enable the development of a ductular reaction. The implications are clear that strategies to minimize or even reverse liver fibrosis will likely also have an effect upon liver regeneration.

## References

1. Alison MR, Islam S, Lim S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. *J Pathol* 2009;217:282–298.
2. Riehle KJ, Dan YY, Campbell JS, Fausto N. New concepts in liver regeneration. *J Gastroenterol Hepatol* 2011;26(Suppl 1):203–212.
3. Furuyama K, Kawaguchi Y, Akiyama H, *et al.* Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. *Nat Genet* 2011;43:34–41.
4. Alison MR, Lin WR. Hepatocyte turnover and regeneration: virtually a virtuoso performance. *Hepatology* 2011;53:1393–1396.
5. Carpentier R, Suñer RE, van Hul N, *et al.* Embryonic ductal plate cells give rise to cholangiocytes, periportal hepatocytes, and adult liver progenitor cells. *Gastroenterology* 2011;141:1432–1438.
6. Iverson SV, Comstock KM, Kundert JA, *et al.* Contributions of new hepatocyte lineages to liver growth, maintenance, and regeneration in mice. *Hepatology* 2011;54:655–663.
7. Fellous TG, Islam S, Tadrous PJ, *et al.* Locating the stem cell niche and tracing hepatocyte lineages in human liver. *Hepatology* 2009;49:1655–1663.
8. DeAngelis RA, Markiewski MM, Kourtzelis I, *et al.* A complement-IL-4 regulatory circuit controls liver regeneration. *J Immunol* 2012;188:641–648.
9. Sgroi A, Gonelle-Gispert C, Morel P, *et al.* Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice. *PLoS One* 2011;6:e25442.

10. Ding BS, Nolan DJ, Butler JM, *et al.* Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration. *Nature* 2010;468:310–315.
11. Wang L, Wang X, Xie G, *et al.* Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. *J Clin Invest* 2012;122:1567–1573.
12. Zhu NL, Asahina K, Wang J, *et al.* Hepatic stellate cell-derived delta-like homolog 1 (DLK1) protein in liver regeneration. *J Biol Chem* 2012;287:10355–10367.
13. Sirma H, Kumar M, Meena JK, *et al.* The promoter of human telomerase reverse transcriptase is activated during liver regeneration and hepatocyte proliferation. *Gastroenterology* 2011;141:326–337.
14. Ng R, Song G, Roll GR, *et al.* A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration. *J Clin Invest* 2012;122:1097–1108.
15. Shu J, Kren BT, Xia Z, *et al.* Genomewide microRNA down-regulation as a negative feedback mechanism in the early phases of liver regeneration. *Hepatology* 2011;54:609–619.
16. Ebrahimkhani MR, Oakley F, Murphy LB, *et al.* Stimulating healthy tissue regeneration by targeting the 5-HT<sub>2B</sub> receptor in chronic liver disease. *Nat Med* 2011;17:1668–1673.
17. Hayashi H, Sakai K, Baba H, *et al.* Thrombospondin-1 is a novel negative regulator of liver regeneration after partial hepatectomy through transforming growth factor-beta1 activation in mice. *Hepatology* 2012;55:1562–1573.
18. Riehle KJ, Campbell JS, McMahan RS, *et al.* Regulation of liver regeneration and hepatocarcinogenesis by suppressor of cytokine signaling 3. *J Exp Med* 2008;205:91–103.
19. Reddy BV, Irvine KD. The Fat and Warts signaling pathways: new insights into their regulation, mechanism and conservation. *Development* 2008;135:2827–2838.
20. Dong J, Feldmann G, Huang J, *et al.* Elucidation of a universal size-control mechanism in *Drosophila* and mammals. *Cell* 2007;130:1120–1133.
21. Zhou D, Conrad C, Xia F, *et al.* Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. *Cancer Cell* 2009;16:425–438.
22. Song H, Mak KK, Topol L, *et al.* Mammalian Mst1 and Mst2 kinases play essential roles in organ size control and tumor suppression. *Proc Natl Acad Sci USA* 2010;107:1431–1436.
23. Yang S, Koteish A, Lin H, *et al.* Oval cells compensate for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease. *Hepatology* 2004;39:403–411.
24. Lowes KN, Brennan BA, Yeoh GC, *et al.* Oval cell numbers in human chronic liver diseases are directly related to disease severity. *Am J Pathol* 1999;154:537–541.
25. Kofman AV, Morgan G, Kirschenbaum A, *et al.* Dose- and time-dependent oval cell reaction in acetaminophen-induced murine liver injury. *Hepatology* 2005;41:1252–1261.
26. Theise ND, Saxena R, Portmann BC, *et al.* The canals of Hering and hepatic stem cells in humans. *Hepatology* 1999;30:1425–1433.
27. Alison MR, Golding M, Sarraf CE, *et al.* Liver damage in the rat induces hepatocyte stem cells from biliary epithelial cells. *Gastroenterology* 1996;110:1182–1190.
28. Boulter L, Govaere O, Bird TG, *et al.* Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. *Nat Med* 2012;18:572–579.
29. Vig P, Russo FP, Edwards RJ, *et al.* The sources of parenchymal regeneration after chronic hepatocellular liver injury in mice. *Hepatology* 2006;43:316–324.
30. Dorrell C, Erker L, Schug J, *et al.* Prospective isolation of a bipotential clonogenic liver progenitor cell in adult mice. *Genes Dev* 2011;25:1193–1203.
31. Bird TG, Lorenzini S, Forbes SJ. Activation of stem cells in hepatic diseases. *Cell Tissue Res* 2008 Jan;331(1):283–300.
32. Hu M, Kurobe M, Jeong YJ, *et al.* Wnt/beta-catenin signaling in murine hepatic transit amplifying progenitor cells. *Gastroenterology* 2007;133:1579–1591.
33. Apte U, Thompson MD, Cui S, Liu B, Cieply B, Monga SP. Wnt/beta-catenin signaling mediates oval cell response in rodents. *Hepatology* 2008;47:288–295.
34. Yang W, Yan HX, Chen L, *et al.* Wnt/beta-catenin signaling contributes to activation of normal and tumorigenic liver progenitor cells. *Cancer Res* 2008;68:4287–4295.
35. Williams JM, Oh SH, Jorgensen M, *et al.* The role of the Wnt family of secreted proteins in rat oval “stem” cell-based liver regeneration: Wnt1 drives differentiation. *Am J Pathol* 2010;176:2732–2742.
36. Darwiche H, Oh SH, Steiger-Luther NC, *et al.* Inhibition of Notch signaling affects hepatic oval cell response in rat model of 2AAF-PH. *Hepat Med* 2011;3:89–98.
37. Ishikawa T, Factor VM, Marquardt JU, *et al.* Hepatocyte growth factor/c-met signaling is required for stem-cell-mediated liver regeneration in mice. *Hepatology* 2012;55:1215–1226.
38. Sicklick JK, Li YX, Melhem A, *et al.* Hedgehog signaling maintains resident hepatic progenitors throughout life. *Am J Physiol Gastrointest Liver Physiol* 2006;290:G859–870.
39. Jakubowski A, Ambrose C, Parr M, *et al.* TWEAK induces liver progenitor cell proliferation. *J Clin Invest* 2005;115:2330–2340.
40. Tirnitz-Parker JE, Viebahn CS, Jakubowski A, *et al.* Tumor necrosis factor-like weak inducer of apoptosis is a mitogen for liver progenitor cells. *Hepatology* 2010;52:291–302.
41. Viebahn CS, Yeoh GC. What fires Prometheus? The link between inflammation and regeneration following chronic liver injury. *Int J Biochem Cell Biol* 2008;40:855–873.
42. Nguyen LN, Furuya MH, Wolfrain LA, *et al.* Transforming growth factor-beta differentially regulates oval cell and hepatocyte proliferation. *Hepatology* 2007;45:31–41.
43. Benhamouche S, Curto M, Saotome I, *et al.* Nf2/Merlin controls progenitor homeostasis and tumorigenesis in the liver. *Genes Dev* 2010;24:1718–1730.
44. Van Hul NK, Abarca-Quinones J, Sempoux C, Horsmans Y, Leclercq IA. Relation between liver progenitor cell expansion and extracellular matrix deposition in a CDE-induced murine model of chronic liver injury. *Hepatology* 2009;49:1625–1635.
45. Lorenzini S, Bird TG, Boulter L, *et al.* Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. *Gut* 2010;59:645–654.
46. Kallis YN, Robson AJ, Fallowfield JA, *et al.* Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response. *Gut* 2011;60:525–533.
47. Pintilie DG, Shupe TD, Oh SH, Salganik SV, Darwiche H, Petersen BE. Hepatic stellate cells’ involvement in progenitor-mediated liver regeneration. *Lab Invest* 2010;90:1199–1208.
48. Paradis V, Youssef N, Dargere D, *et al.* Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. *Hum Pathol* 2001;32:327–332.

49. Marshall A, Rushbrook S, Davies SE, *et al.* Relation between hepatocyte G1 arrest, impaired hepatic regeneration, and fibrosis in chronic hepatitis C virus infection. *Gastroenterology* 2005;128:33–42.
50. Ikeda H, Sasaki M, Sato Y, *et al.* Large cell change of hepatocytes in chronic viral hepatitis represents a senescent-related lesion. *Hum Pathol* 2009;40:1774–1782.
51. Falkowski O, An HJ, Ianus IA, *et al.* Regeneration of hepatocyte “buds” in cirrhosis from intrabiliary stem cells. *J Hepatol* 2003;39:357–364.
52. Lin WR, Lim SA, McDonald SA, *et al.* The histogenesis of regenerative nodules in human liver cirrhosis. *Hepatology* 2010;51:1017–1026.
53. Alison MR, Nicholson LJ, Lin WR. Chronic inflammation and hepatocellular carcinoma. *Recent Results in Cancer Res* 2011; 185:135–148.
54. Sell S, Pierce GB. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. *Lab Invest* 1994;70:6–22.
55. Hixson DC, Brown J, McBride AC, Affigne S. Differentiation status of rat ductal cells and ethionine-induced hepatic carcinomas defined with surface-reactive monoclonal antibodies. *Exp Mol Pathol* 2000;68:152–169.
56. Yamashita T, Forgues M, Wang W, *et al.* EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. *Cancer Res* 2008;68:1451–1461.
57. Lee JS, Heo J, Libbrecht L, *et al.* A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. *Nat Med* 2006;12:410–416.
58. Durnez A, Verslype C, Nevens F, *et al.* The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma: a possible progenitor cell origin. *Histopathology* 2006;49:138–151.
59. Kim H, Choi GH, Na DC, *et al.* Human hepatocellular carcinomas with “Stemness”-related marker expression: keratin 19 expression and a poor prognosis. *Hepatology* 2011;54:1707–1717.
60. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells; problems for therapy? *J Pathol* 2011;223:147–161.
61. Wang XQ, Ongkeko WM, Chen L, *et al.* Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway. *Hepatology* 2010;52:528–539.
62. Lee TK, Castilho A, Cheung VC, *et al.* Lupeol targets liver tumor-initiating cells through phosphatase and tensin homolog modulation. *Hepatology* 2011;53:160–170.
63. Cheung ST, Cheung PF, Cheng CK, Wong NC, Fan ST. Granulin-epithelin precursor and ATP-dependent binding cassette (ABC) B5 regulate liver cancer cell chemoresistance. *Gastroenterology* 2011;140:344–355.
64. Yamashita T, Honda M, Nio K, *et al.* Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. *Cancer Res* 2010;70:4687–4697.
65. Alison MR, Lin WR, Lim SM, Nicholson LJ. Cancer stem cells: in the line of fire. *Cancer Treat Rev* 2012;38:589–598.
66. Forbes SJ, Parola M. Liver fibrogenic cells. *Best Pract Res Clin Gastroenterol* 2011;25:207–217.

# Chapter 2

## Hepatic immunology

Gyongyi Szabo and Johanna Bruneau

*University of Massachusetts Medical School, Worcester, MA, USA*

### Summary

The immune system is an integral part of the liver as an organ. In addition to the classical roles of hepatocytes and biliary cells in metabolism and digestion, the presence of a broad range of immune cells in the liver contributes to its basic functions by sensing and reacting to external and endogenous danger signals. Several unique features characterize immune responses in the liver including the composition of immune cell types, the local tissue environment that allows close interaction between parenchymal cells and immune cells, and the gut-derived signals arriving from the portal blood. Integration of these components is pivotal for immunological homeostasis in the liver and orchestration of effective immune responses for the protection of the host.

### Overview of liver immunology

The liver is a unique immunological organ due to its cellular composition and physiological function (Table 2.1). Cells of the innate and adaptive immune system actively participate in immune responses in the liver, recognizing and eliminating pathogens and other danger signals and inducing antigen-specific adaptive immune responses. Another key function of the liver is to protect the host from the presence of undesirable activated immune cells. Several factors discriminate the liver from other organs with respect to immune response. The liver is constantly exposed to gut-derived substances such as antigens, nutrients, and metabolites, as well as pathogen-derived immune activation signals from the portal circulation. The normal liver immune environment promotes immunological tolerance, which has long been recognized in the setting of liver transplantation. While the exact mechanisms for this have yet to be delineated, the presence of predominantly immature dendritic cells that induce immune tolerance instead of T cell activation and high levels of immuno-inhibitory cytokines and mediators (interleukin 10 [IL10], transforming growth factor beta [TGF $\beta$ ], and prostaglandin

E2 [PGE $_2$ ]) contribute to this phenomenon. The architecture of liver sinusoids, with slow blood flow and close proximity of liver parenchymal cells and immune cells, creates a microenvironment for prolonged interactions between these cells that may also be a factor in local immune regulation. Finally, the composition of the liver T cell and natural killer (NK)–natural killer T (NKT) cell populations is markedly different from that of the circulation and many organs, with high proportional representation of NK, NKT, and gamma delta ( $\gamma\delta$ ) T cells.

### Innate immunity

Innate immunity provides the first line of host defense against invading pathogens. In recent years, it was discovered that in addition to pathogens that trigger an innate immune response, the innate immune response can also recognize and respond to damaged self-molecules. A coordinated cascade of events occurs that involves recognition of exogenous or endogenous danger signals by various pattern recognition receptors. This leads to a rapid induction of intracellular signaling cascades that direct the production of pro-inflammatory

**Table 2.1** The liver is a unique immune organ.

The largest immune organ
Unique biological properties
<ul style="list-style-type: none"> <li>• Unique architecture and vascular structure that facilitate interaction between parenchymal and nonparenchymal cells and circulating immune cells</li> <li>• Constant exposure to gut-derived antigens and pathogen-derived substances from the portal circulation</li> </ul>
Unusual composition of lymphocyte subsets
<ul style="list-style-type: none"> <li>• NK cells, NKT cells, and T cell receptor repertoire (<math>\gamma</math> and <math>\delta</math>)</li> </ul>
Promotes immune tolerance
<ul style="list-style-type: none"> <li>• IL10, PGE<sub>2</sub>, and TGF<math>\beta</math></li> <li>• Diversity of professional and nonprofessional antigen-presenting cells</li> </ul>

cytokines and/or type I interferons that comprise innate immunity. Innate immunity is also critical in triggering and modifying adaptive immune responses [1].

## Cell populations and mediators in the innate immune response

### *Monocytes, macrophages, and Kupffer cells*

Monocytes and macrophages represent the major constituents of the innate immune cell population. These cells originate in the bone marrow and can be rapidly recruited to sites of inflammation due to their chemotactic and cell migration properties. Circulating monocytes differentiate into macrophages at sites of infection, injury, or inflammation in the tissues [2]. Kupffer cells are the resident macrophages in the liver; they contribute to elimination of gut-derived pathogens and play important roles in various liver diseases, including alcoholic and nonalcoholic liver diseases [3, 4].

Monocytes, macrophages, and Kupffer cells are the classical “phagocytic” immune cells that uptake pathogens or cell debris by phagocytosis, endocytosis, or pinocytosis. The phagocytic capacity of these cells also includes production of reactive oxygen species (ROS) that contribute to their antibacterial effector function and production of pro-inflammatory cytokines. Monocytes, macrophages, and Kupffer cells have overlapping functional repertoires where macrophages and Kupffer cells are most potent in pro-inflammatory cytokine and ROS production and relatively inefficient in antigen presentation compared to circulating blood monocytes [2].

Monocytes migrate from the circulation into the tissue, where they differentiate into tissue-specific macrophages, such as Kupffer cells in the liver. There are two main populations of monocytes, the classical and

nonclassical subsets, which vary in phenotype, function, and morphology. The classical subset, which comprises approximately 90% of circulating monocytes, expresses high levels of CD14 (CD14<sup>++</sup>). The nonclassical subset is distinguished by expression of CD16 (Fc $\gamma$  receptor III) and variable CD14 expression [5]. CD14<sup>+</sup>CD16<sup>+</sup> monocytes have been identified as the main producers of tumor necrosis factor alpha (TNF $\alpha$ ) [6] and secrete more IL10 in response to lipopolysaccharide (LPS) stimulation than CD14<sup>dim</sup>CD16<sup>+</sup> or CD14<sup>+</sup>CD16<sup>-</sup> cells [5]. It has been reported that the pro-inflammatory CD14<sup>+</sup>CD16<sup>+</sup> monocyte population is expanded in the circulation and liver of patients with chronic liver disease. In addition, the investigators report that CD14<sup>+</sup>CD16<sup>+</sup> cells directly activate hepatic stellate cells, but CD14<sup>+</sup>CD16<sup>-</sup> cells do not [7]. Therefore, the CD14<sup>+</sup>CD16<sup>+</sup> monocyte subset may contribute to an inflammatory and pro-fibrogenic intrahepatic microenvironment, which would affect the progression of liver disease. Another nonclassical monocyte subset, CD14<sup>-</sup>CD16<sup>+</sup> cells, is more responsive to Toll-like receptor 8 (TLR8) stimulation than CD14<sup>+</sup>CD16<sup>-</sup> cells [8]. Phenotypically, monocytes of the classical lineage are larger and denser, capable of phagocytosis and production of ROS. In contrast, nonclassical monocytes are smaller, less dense cells, with better antigen presentation function [9–12].

Circulating monocytes are recruited into the target tissue by a coordinated sequence of signals. Chemokines regulate the expression of a number of integrins, which are cell surface receptors that interact with adhesion molecules on the endothelial cells’ surface, enabling the monocyte to attach to and roll along the endothelium. Integrins are also involved in polarization of the monocyte, which allows it to extravasate into the tissue. Once inside the tissue, monocytes differentiate into dendritic cells or macrophages [13]. Since monocytes are a heterogeneous cell population, as described in this section, the stage at which they are recruited into the tissue may influence the final cell type [2].

Macrophages are an important component of immunological defense. Firstly, they act as an integral part of the innate immune response by engulfing pathogens and killing them via the release of ROS. Recognition of these pathogens also stimulates macrophages to release cytokines and chemokines, which recruit other cells to the site of infection. Macrophages also contribute to the adaptive immune response by processing and presenting antigens to activate T and B cells, components of the adaptive immune response [14]. Due to their extensive phagocytic capacity, macrophages also play an important part in the clearance of cellular debris that arises from necrosis and apoptosis [2]. Macrophages secrete a number of different classes of molecules depending on their activation status, including pro-inflammatory



cytokines such as IL1 $\beta$ , TNF $\alpha$ , and IL6; anti-inflammatory cytokines IL10 and TGF $\beta$ ; chemokines; and proteolytic enzymes [15].

Classically activated macrophages (also referred to as M1 macrophages) are generated in response to Th1 cytokines, the most important activator being interferon gamma (IFN $\gamma$ ) [14, 16]. IFN $\gamma$  activates IFN regulatory factor (IRF) transcription factors, including IRF1. IRF1 upregulates IFN $\alpha$ , IFN $\beta$ , and inducible nitric oxide synthase (iNOS), increasing the antiviral and antimicrobial properties of the affected cell [14]. This cell type secretes a number of inflammatory cytokines that amplify the Th1 immune response. Classical macrophages are able to kill intracellular pathogens by producing ROS and nitric oxide [17]. These cells are an important element in the innate immune response in addition to being potent mediators of inflammation [18].

Alternatively activated macrophages (also known as M2 macrophages) are generated in response to Th2 cytokines IL4 and IL13 [15]. Activation along this pathway enhances endocytic antigen uptake and presentation, eosinophil involvement, and granuloma formation that is required for an efficient response to parasitic infection or extracellular pathogens [14]. This cell type is distinct from classical macrophages in that they do not produce nitric oxide [17].

Macrophages play an important role in liver fibrosis. Macrophages produce the pro-fibrotic cytokine TGF $\beta$  [15, 17]. In addition, alternatively activated macrophages may be involved in production of the extracellular matrix [17]. However, current evidence suggests that liver macrophages act as regulators of fibrosis and fibrogenesis [19].

Kupffer cells are liver resident macrophages. They account for approximately 80% of the body's macrophage population [20], and constitute approximately 20% of the nonparenchymal cells in the liver [21]. Kupffer cells are localized to the sinusoidal vascular space in the periportal area. In this location, they are able to clear endotoxins, microorganisms, and cellular debris from the portal circulation entering the liver [20, 21]. Kupffer cells act cooperatively with neutrophils to eliminate pathogens from the blood [20, 22]. In addition, Kupffer cells are important producers of cytokines and chemokines in the liver following injury or endotoxemia [23].

### ***Dendritic cells and antigen presentation***

Dendritic cells (DCs) are the main type of antigen-presenting cells in the immune system that uptake antigens, induce antigen-specific T cell activation, and produce inflammatory and immunomodulatory cytokines. DCs are 10 times more potent at antigen presentation and T cell activation compared to mono-

cytes and macrophages. Dendritic cells efficiently uptake and process antigens due to their rich subcellular endosomal compartments. The processed antigenic peptides are presented in the context of major histocompatibility complex class (MHC) II molecule and co-stimulatory signals to initiate activation of naïve CD4<sup>+</sup> T lymphocytes [24].

Dendritic cells can be separated into various subtypes based on their origin, cell surface marker expression, and functional capacity. Myeloid DCs are derived from the bone marrow and are present in both murine and human livers. Blood monocytes can differentiate into monocyte-derived myeloid dendritic cells upon *ex vivo* stimulation with IL4 and granulocyte-macrophage colony-stimulating factor (GM-CSF). Differentiation of circulating monocytes into dendritic cells is triggered *in vivo* by the tissue environment. Both conventional and monocyte-derived DCs (mDCs) produce the immunomodulatory cytokines IL12 and IL10 that contribute to the efficiency of their T cell activation and antigen-presenting capacity. The mDC1 (myeloid CD1c<sup>+</sup> DC) represents the largest population of myeloid DCs (also known as conventional DCs) in the blood, which produce inflammatory cytokines and chemokines upon stimulation [25]. The mDC2 (myeloid CD141<sup>+</sup> DC or myeloid BDCA3<sup>+</sup> DC) represents a minor subset of blood leukocytes that have recently been identified as the human homologue of the mouse CD8<sup>+</sup> DC subset [26, 27]. mDC2s are major producers of IL12 and cross-present antigen for CD8 class 1-restricted cytotoxic T lymphocyte (CTL) responses under TLR3 ligation [28, 29]. Plasmacytoid DCs (pDCs) represent a small population in the peripheral blood but are enriched in the liver; they are the most potent producers of IFN $\alpha$  in viral infections [30].

Both mDCs and pDCs are present in the liver in an immature phenotype that is characterized by a high capacity to uptake antigens but relatively low T cell activation potential. Compared to other tissues, the majority of DCs in the liver possess an immature phenotype. This phenomenon has been attributed to the state of "immune tolerance" in the liver. Pathogen-derived signals, in the presence of inflammation, rapidly induce maturation of immature DCs in the tissue. During the maturation progress, DCs change their phenotype and increase surface expression of T cell co-stimulatory molecules, resulting in their superior antigen presentation and T cell activation capacity [30, 31].

### ***NK and NKT cells***

NK and NKT cells are lymphocytes that, unlike B and T cells, do not express an antigen receptor with somatic diversification [32]. Human NK cells express CD56 and CD16 but lack CD3. NK cells constitute up to 50% of the

hepatic lymphocyte population in humans, compared to 5–20% in the peripheral circulation [31]. In addition to their increased numbers, liver-derived NK cells also exhibit enhanced cytotoxic capacity against tumor cells compared to splenic and peripheral blood NK cells derived from rodents or humans [32].

NK cell function is regulated by a balance between stimulatory and inhibitory receptors that are constitutively expressed on the cell surface. NK cells are inactivated when inhibitory receptors bind to MHC I receptors on the target cell [32]. NK cells become activated when a cell with abnormal expression of MHC I or stress-related proteins is detected. Upon activation, NK cells release granules that lyse the target cells, or they induce apoptosis via engagement of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) [31, 32].

Hepatic NK cells are important mediators of the innate immune response against tumors, viruses, intracellular bacteria, and parasites. Decreases in the number of NK cells are associated with progression of hepatocellular carcinoma [32] and chronic hepatitis C virus (HCV) infection [31]. Activated NK cells also play a role in liver injury and repair by controlling the balance between pro-inflammatory and anti-inflammatory cytokines in the liver microenvironment [21].

NKT cells express T cell markers as well as NK cell markers. Classical NKT cells (also known as invariant NKT or iNKT cells), which are CD1d dependent, are capable of producing type I and type II cytokines. Similar to NK cells, iNKT cells can induce cell lysis via perforin or the Fas ligand. Nonclassical NKT cells, which are CD1d independent, produce only type I cytokines. The number of NKT cells is enriched in the liver, comprising up to 10% of the liver lymphocyte population [32]. NKT cells recognize nonpeptide antigens such as lipid and glycolipid and, when stimulated, are able to rapidly secrete large amounts of IFN $\gamma$  and IL4, influencing the balance between a pro- and anti-inflammatory microenvironment in the liver [21]. These characteristics suggest that NKT cells are involved in connecting the innate and adaptive immune responses in the liver [32]. NKT-mediated cytotoxicity has been identified as a key factor in experimental hepatitis models induced by concanavalin A and endotoxin. NKT cells are also important in protecting against liver infection. NKT- or CD1d-deficient mice are more susceptible to certain viral infections, and NKT cells activated by the CD1d ligand downregulate HBV replication via induction IFN $\gamma$  secretion [21].

$\gamma\delta$  T cells are an alternative T cell type that express a  $\gamma\delta$  T cell receptor instead of the more common  $\alpha\beta$  T cell receptor [31]. These cells recognize stress proteins and nonprotein antigens. Although their number is limited in the circulation, they comprise between 15 and 25% of

the liver T cell population [21]. It has been shown that  $\gamma\delta$  T cell numbers increase in patients with viral hepatitis but not in those with nonviral hepatitis [32]. It has also been reported that hepatic  $\gamma\delta$  T cells are elevated in mice with viral infection or liver tumors [31, 32], indicating that this cell type plays a role in immune surveillance in the liver.

### *Neutrophil leukocytes*

Neutrophil leukocytes are the first line of defense in most bacterial infections and in tissue damage. Regulated expression of a cadre of adhesion molecules permits leukocytes to rapidly invade inflamed tissue from the microvessels of the circulation [33]. Neutrophils are highly chemotactic and exert direct antibacterial effects through their expression of elastase, myeloperoxidases, and ROS. Although neutrophils are primarily involved in the clearance of infection, they have also been implicated in the initiation of tissue damage in alcoholic liver disease and sepsis [23].

### *Cytokines, interferons, and chemokines*

Cytokines, interferons, and chemokines are soluble protein “messengers” and executors of innate and adaptive immune responses. Cytokines are soluble signaling molecules that provide communication between different cells in the tissue, in the systemic circulation, and in distant organs; they have paracrine and autocrine effects. The interleukin family of cytokines can be divided into various categories of cytokines that promote inflammation including IL1 $\alpha$ , IL1 $\beta$ , IL6, and several other types of cytokines such as IL17. IL10 is an anti-inflammatory cytokine that also has negative effects on antigen-presenting functions of innate immune cells and directly inhibits T cell proliferation. Other cytokines such as TNF $\alpha$ , IL12, IL18, IL33, IL21, and IL22 have immunoregulatory functions [34].

The pro-inflammatory cytokine TNF $\alpha$  is primarily synthesized by monocytic cells, including macrophages, Kupffer cells, and microglia. There are two receptors for TNF $\alpha$ , TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). TNFR1 is expressed on most tissues, while TNFR2 is expressed mainly on immune cells. TNF $\alpha$  is released during infection or trauma, and is able to generate a cytokine cascade [35]. Several studies have noted that TNF $\alpha$  is an important mediator in the development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in both humans and animals [36].

The IL1 family of cytokines includes IL1 $\alpha$ , IL1 $\beta$ , IL18, IL33, and the IL1 receptor antagonist (IL1RA). These cytokines have important roles in the innate and adap-